LOS ANGELES, April 1, 2013 /PRNewswire/ -- ImaginAb, Inc., a clinical-stage company developing in vivo molecular imaging agents based on antibody technology, today announced that it has changed its name to AmaginAb. During a 'strategy meeting' at a recent employee team-building event, the Company's management belatedly realized that most of the important companies in the biotechnology space begin with the letter 'A'.
"It became clear by the third hot chocolate one evening during our annual company ski trip that we were going about this biotechnology thing the wrong way," said Dr. Christian Behrenbruch , Chief Executive Officer of ImaginAb. "There just aren't that many impressive companies in our field that begin with the letter 'I'. We were forced to acknowledge that we might never get acquired with a name that starts with 'I'."
Dr. Jean Gudas , ImaginAb's VP of R&D similarly commented, "After two decades working at Amgen, Abgenix, Agensys - which became Astellas, not coincidentally - I just felt really uncomfortable when I moved to ImaginAb, an antibody engineering company beginning with the letter 'I.' In addition, we receive a constant stream of CVs from Amgen employees looking for a more exciting place to work and so we want to make them feel at home."
"This matter initially caused a great deal of consternation with our Board of Directors," stated Dr. Anna Wu , ImaginAb's Co-Founder and Chief Scientist. "However, one of our Directors is from New Zealand and has always pronounced the company 'Am-agin-Ab' so he couldn't see the issue. Once everyone realized that we'd be joining the esteemed A-list of biotechnology companies and would henceforth appear at the top of the lineup on every conference program, our board was immediately supportive."
The name change is in full force and effect as of April 1st 2013. For more information about this important announcement, please visit www.amaginab.com.
AmaginAb is redefining therapeutic management by harnessing the power of antibody technology for in vivo imaging. The company's proprietary antibody fragment platform yields actionable molecular information to guide treatment decisions in cancer and immunology. AmaginAb also collaborates with select biopharmaceutical partners to design imaging agents as companion diagnostics for therapeutic antibodies. AmaginAb's technology is positioned to deliver on the promise of precision medicine by improving patient outcomes and reducing the cost of healthcare.
This release is being issued by ImaginAb, Inc. and is an acknowledged spoof release. The news is not factual and should not be reported on as such.
|SOURCE ImaginAb, Inc.|
Copyright©2012 PR Newswire.
All rights reserved